Cancer Research Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06253130
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
-
NCT04717414
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking...
-
NCT05685004
Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchThis clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and...
-
NCT04083599
GCT1042-01: A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaGEN1042 is a bispecific antibody that crosslinks CD40 on antigen-presenting cells with 4-1BB on activated T cells, thereby inducing conditional stimulation of and co-stimulatory activity on both cell...
-
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...
-
NCT05629585
D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaWe are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug...
-
NCT05645692
B044157 A Phase II, Randomized, Multicenter, Open-Label, Controlled Study Of R07247669 Alone Or In Combination With Tiragolumab Versus Atezolizumab In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Bladder Cancer Who Are Ineligible For Platinum-Containing Chemotherapy
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
Comparative effectiveness of Juntos Después del Cáncer (JDC) among Breast Cancer Survivors and their Intimate Partners
This study is not currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05945433
Growth and Tolerance of Preterm Infants Fed an Experimental Human Milk Fortifier
This study is not currently enrolling.Associated Conditions: NeonatalResearch Area: Clinical Cancer ResearchYou are being asked to allow your baby to take part in this research study because he/she was born prematurely. Because your baby was born early, he/she will have a human milk fortifier (HMF) added to...
-
NCT05364073
FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer ResearchThe purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with...